Mechanisms of Taxol resistance related to microtubules

Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.

[1]  W. Hait,et al.  A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  W. B. Derry,et al.  Substoichiometric binding of taxol suppresses microtubule dynamics. , 1995, Biochemistry.

[3]  N. Cowan,et al.  Diverse mechanisms in the generation of human beta-tubulin pseudogenes. , 1982, Science.

[4]  M. Gonzalez-Garay,et al.  A β-Tubulin Leucine Cluster Involved in Microtubule Assembly and Paclitaxel Resistance* 210 , 1999, The Journal of Biological Chemistry.

[5]  G. Hudes,et al.  Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. , 1998, Biochimica et biophysica acta.

[6]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Sikic,et al.  Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. , 1995, Oncology research.

[8]  G. Gundersen,et al.  Microtubules and signal transduction. , 1999, Current opinion in cell biology.

[9]  S. Horwitz,et al.  Mechanisms of Taxol-induced cell death are concentration dependent. , 1998, Cancer research.

[10]  M. Kavallaris,et al.  The role of β-tubulin isotypes in resistance to antimitotic drugs , 2001 .

[11]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[12]  Terry L. Smith,et al.  Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Lanfranchi,et al.  TUBA8: A new tissue-specific isoform of alpha-tubulin that is highly conserved in human and mouse. , 2000, Biochemical and biophysical research communications.

[14]  S. Horwitz,et al.  The Microtubule-destabilizing Activity of Metablastin (p19) Is Controlled by Phosphorylation* , 1997, The Journal of Biological Chemistry.

[15]  I. Bièche,et al.  Overexpression of the stathmin gene in a subset of human breast cancer. , 1998, British Journal of Cancer.

[16]  T. Fojo,et al.  Molecular effects of paclitaxel: Myths and reality (a critical review) , 1999, International journal of cancer.

[17]  M. Jordan,et al.  Microtubule dynamics: taking aim at a moving target. , 1995, Chemistry & biology.

[18]  D. Braguer,et al.  Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Cassimeris.  The oncoprotein 18/stathmin family of microtubule destabilizers. , 2002, Current opinion in cell biology.

[20]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[21]  R. Wade,et al.  Microtubule structure at improved resolution. , 2001, Biochemistry.

[22]  N. Saijo,et al.  Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells , 2001, Cancer.

[23]  R. Luduena,et al.  Removal of beta III isotype enhances taxol induced microtubule assembly. , 1993, Cell structure and function.

[24]  M. Fukuoka,et al.  Mutational analysis of the β-tubulin gene in lung cancer , 2002 .

[25]  R. Kuick,et al.  Identification of a polypeptide associated with the malignant phenotype in acute leukemia. , 1988, The Journal of biological chemistry.

[26]  T. Fojo,et al.  Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  K. Downing,et al.  Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. , 2000, Annual review of cell and developmental biology.

[28]  T. Mitchison,et al.  Identification of a Protein That Interacts with Tubulin Dimers and Increases the Catastrophe Rate of Microtubules , 1996, Cell.

[29]  R. Rosell,et al.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Nishida,et al.  Activation of microtubule-associated protein kinase by microtubule disruption in quiescent rat 3Y1 cells. , 1991, Experimental cell research.

[31]  H. Rosenkranz,et al.  Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. , 1996, Biochemistry.

[32]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[33]  J. Bulinski,et al.  Abundant expression of the microtubule-associated protein, ensconsin (E-MAP-115), alters the cellular response to Taxol. , 2001, Cell motility and the cytoskeleton.

[34]  E. Nogales,et al.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Mitchison,et al.  Microtubule polymerization dynamics. , 1997, Annual review of cell and developmental biology.

[37]  M. Kavallaris,et al.  Microtubule alterations and resistance to tubulin-binding agents (review). , 2002, International journal of oncology.

[38]  T. Ohira,et al.  Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line , 1994, Japanese journal of cancer research : Gann.

[39]  Eva Nogales,et al.  New insights into microtubule structure and function from the atomic model of tubulin , 1998, European Biophysics Journal.

[40]  Jun Yao,et al.  Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. , 1998, Molecular cell.

[41]  I. Ringel,et al.  3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. , 1994, The Journal of biological chemistry.

[42]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[43]  D. Kingston,et al.  Characterization of the Taxol Binding Site on the Microtubule , 1995, The Journal of Biological Chemistry.

[44]  S. Arkin,et al.  Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. , 2000, Cancer research.

[45]  G. Hudes,et al.  Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. , 1998, British Journal of Cancer.

[46]  S. Mani,et al.  Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  L. Murphy,et al.  Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  B. Segerman,et al.  Mutations of Oncoprotein 18/Stathmin Identify Tubulin-Directed Regulatory Activities Distinct from Tubulin Association , 1999, Molecular and Cellular Biology.

[49]  S. Arkin,et al.  Effects of stathmin inhibition on the mitotic spindle. , 2001, Journal of cell science.

[50]  F. Cabral,et al.  A Mechanism of Cellular Resistance to Drugs that Interfere with Microtubule Assembly a , 1986, Annals of the New York Academy of Sciences.

[51]  E. Nogales,et al.  High-Resolution Model of the Microtubule , 1999, Cell.

[52]  F. Gros,et al.  Polyglutamylation of tubulin as a progressive regulator of in vitro interactions between the microtubule-associated protein Tau and tubulin. , 1994, Biochemistry.

[53]  M. Kavallaris,et al.  Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol , 1999, British Journal of Cancer.

[54]  T. MacRae.  Tubulin post-translational modifications--enzymes and their mechanisms of action. , 1997, European journal of biochemistry.

[55]  C. Fairchild,et al.  Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). , 1998, Cancer research.

[56]  D. Brown,et al.  Expression and posttranslational modification of class III beta-tubulin during neuronal differentiation of P19 embryonal carcinoma cells. , 1996, Cell motility and the cytoskeleton.

[57]  A. Banerjee,et al.  Differential Assembly Kinetics of α-Tubulin Isoforms in the Presence of Paclitaxel , 1998 .

[58]  Claudia J. Bode,et al.  Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. , 2002, Biochemistry.

[59]  F. Wang,et al.  Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. , 2003, Biochemistry.

[60]  P. Hollenbeck.  Cytoskeleton: Microtubules get the signal , 2001, Current Biology.

[61]  Arun K. Ghosh,et al.  The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. , 2002, Biochemistry.

[62]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[63]  S. Horwitz,et al.  Novel molecules that interact with microtubules and have functional activity similar to Taxol. , 2001, Drug discovery today.

[64]  A. Levine,et al.  DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. , 1999, Cancer research.

[65]  R. Luduena,et al.  Preparation of a monoclonal antibody specific for the class IV isotype of beta-tubulin. Purification and assembly of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers from bovine brain. , 1992, The Journal of biological chemistry.

[66]  P. Dent,et al.  Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. , 2001, Cancer research.

[67]  L. Cardone,et al.  A-kinase anchor protein 84/121 are targeted to mitochondria and mitotic spindles by overlapping amino-terminal motifs. , 2002, Journal of molecular biology.

[68]  S. Schreiber,et al.  (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. , 1996, Chemistry & biology.

[69]  Kenneth H. Downing,et al.  Structure of the αβ tubulin dimer by electron crystallography , 1998, Nature.

[70]  G A Orr,et al.  Photoaffinity labeling approach to map the Taxol-binding site on the microtubule. , 1998, Methods in enzymology.

[71]  M. Hung,et al.  Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. , 2002, Molecular cell.

[72]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[73]  E. Nogales.  Structural insights into microtubule function. , 2000, Annual review of biochemistry.

[74]  D. Kingston,et al.  A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. , 2000, Biochemistry.

[75]  S. Barlow,et al.  Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[77]  K. Sullivan,et al.  Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[78]  S. Horwitz,et al.  Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. , 2003, Cancer research.

[79]  R. Luduena,et al.  In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins. , 1994, The Journal of biological chemistry.

[80]  P. Giannakakou,et al.  The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. , 1997, Molecular pharmacology.

[81]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[82]  D. Menick,et al.  Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. , 1999, Journal of cell science.

[83]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[84]  G. Mills,et al.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.

[85]  S. Barlow,et al.  Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. , 1991, The Journal of biological chemistry.

[86]  K. Nylander,et al.  Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas , 1995, The Histochemical Journal.

[87]  I. Bièche,et al.  Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours , 1999, British Journal of Cancer.

[88]  S. Horwitz,et al.  Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. , 2002, Cancer research.

[89]  B. Rossi,et al.  Microtubule Integrity Regulates Src-like and Extracellular Signal-regulated Kinase Activities in Human Pro-monocytic Cells , 1998, The Journal of Biological Chemistry.

[90]  A. Tolcher.  Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel. , 2001, The oncologist.

[91]  C. Dumontet,et al.  Differentiation of human colon cancer cells changes the expression of β-tubulin isotypes and MAPs , 1999, British Journal of Cancer.

[92]  I. Ringel,et al.  Direct photoaffinity labeling of tubulin with taxol. , 1992, Journal of the National Cancer Institute.

[93]  A. Levine,et al.  The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells , 1998, Oncogene.

[94]  M. Kavallaris,et al.  Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. , 2001, Cancer research.

[95]  M. G. Lee,et al.  Evidence that a human β-tubulin pseudogene is derived from its corresponding mRNA , 1982, Nature.

[96]  P. Oefner,et al.  Re: Genetic Analysis of the β-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer , 2002 .

[97]  R. B. Montgomery,et al.  Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[98]  M. Monden,et al.  Mutational analysis of the class I β‐tubulin gene in human breast cancer , 2002 .

[99]  G. Piszczek,et al.  Conformation of microtubule-bound paclitaxel determined by fluorescence spectroscopy and REDOR NMR. , 2000, Biochemistry.

[100]  D. Panda,et al.  Microtubule dynamics in vitro are regulated by the tubulin isotype composition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[101]  G. Hudes,et al.  Modulation of endogenous β-tubulin isotype expression as a result of human βIII cDNA transfection into prostate carcinoma cells , 2001, British Journal of Cancer.

[102]  H. Gradin,et al.  Oncoprotein 18 is a phosphorylation‐responsive regulator of microtubule dynamics. , 1996, The EMBO journal.

[103]  Jonathan A. Cooper,et al.  Differential Modulation of Mitogen-activated Protein (MAP) Kinase/Extracellular Signal-related Kinase Kinase and MAP Kinase Activities by a Mutant Epidermal Growth Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[104]  M. Kohonen-Corish,et al.  Lack of β‐tubulin gene mutations in early stage lung cancer , 2002 .

[105]  G. C. Rogers,et al.  Microtubule motors in mitosis , 2000, Nature.

[106]  E. Nogales,et al.  Refined structure of alpha beta-tubulin at 3.5 A resolution. , 2001, Journal of molecular biology.

[107]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[108]  M. G. Lee,et al.  Evolutionary history of a multigene family: An expressed human β-tubulin gene and three processed pseudogenes , 1983, Cell.

[109]  R. Luduena.  Multiple forms of tubulin: different gene products and covalent modifications. , 1998, International review of cytology.

[110]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[111]  P. Chacón,et al.  Changes in Microtubule Protofilament Number Induced by Taxol Binding to an Easily Accessible Site , 1998, The Journal of Biological Chemistry.

[112]  B. Oakley.  An abundance of tubulins. , 2000, Trends in cell biology.

[113]  J. Snyder,et al.  The binding conformation of Taxol in β-tubulin: A model based on electron crystallographic density , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[114]  L. Amos,et al.  Crystal structure of the bacterial cell-division protein FtsZ , 1998, Nature.

[115]  W. Telford,et al.  Multidrug resistance , 1988 .

[116]  K. Nicolaou,et al.  The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. , 1999, Biochemistry.

[117]  D. O’Rourke,et al.  Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters β-Tubulin Isotype Expression* , 2000, The Journal of Biological Chemistry.

[118]  Michael J. Kelley,et al.  Genetic Analysis of the β-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer , 2001 .

[119]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[120]  S. Ng,et al.  Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines , 2000 .

[121]  J. Manfredi,et al.  Taxol binds to cellular microtubules , 1982, The Journal of cell biology.

[122]  P. Denoulet,et al.  Tubulin polyglutamylase: isozymic variants and regulation during the cell cycle in HeLa cells. , 1999, Journal of cell science.

[123]  J. Bulinski,et al.  Differential expression of alternatively spliced forms of MAP4: a repertoire of structurally different microtubule-binding domains. , 1995, Biochemistry.

[124]  S. Hisanaga,et al.  Phosphorylation of MAP4 affects microtubule properties and cell cycle progression. , 2001, Journal of cell science.

[125]  R. Luduena,et al.  Phosphorylation of III -Tubulin , 1996 .

[126]  E. Nieves,et al.  Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines. , 2001, Biochemistry.

[127]  R. Luduena,et al.  Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. , 1990, The Journal of biological chemistry.

[128]  M. Bornens,et al.  Glutamylation of centriole and cytoplasmic tubulin in proliferating non-neuronal cells. , 1998, Cell motility and the cytoskeleton.

[129]  W. B. Derry,et al.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. , 1997, Biochemistry.

[130]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  F. Gros,et al.  Interaction of kinesin motor domains with alpha- and beta-tubulin subunits at a tau-independent binding site. Regulation by polyglutamylation. , 1996, The Journal of biological chemistry.

[132]  E. Nogales,et al.  Cold Adaptation of Microtubule Assembly and Dynamics , 2000, The Journal of Biological Chemistry.

[133]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[134]  J. Díaz,et al.  Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. , 1993, Biochemistry.

[135]  P. Denoulet,et al.  Differential Binding Regulation of Microtubule-associated Proteins MAP1A, MAP1B, and MAP2 by Tubulin Polyglutamylation* , 2001, The Journal of Biological Chemistry.

[136]  S. Danishefsky,et al.  Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[137]  G A Orr,et al.  Characterization of the Taxol Binding Site on the Microtubule , 1999, The Journal of Biological Chemistry.

[138]  S. Horwitz,et al.  Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. , 2001, Molecular pharmacology.